| scholarly article | Q13442814 |
| P50 | author | Malin Sund | Q44140722 |
| P2093 | author name string | Christina Lundin | |
| Daniel Öhlund | |||
| Erik Lundberg | |||
| Oskar Franklin | |||
| Henrik Antti | |||
| Pär Jonsson | |||
| Hanna Nyström | |||
| Ola Billing | |||
| P2860 | cites work | A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 |
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates | Q26865015 | ||
| MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis | Q28300240 | ||
| Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer | Q28478758 | ||
| Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue | Q28730615 | ||
| Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis | Q29547575 | ||
| A novel and universal method for microRNA RT-qPCR data normalization | Q33468633 | ||
| The Västerbotten Intervention Programme: background, design and implications | Q33750597 | ||
| MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias | Q34082610 | ||
| Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer | Q34310243 | ||
| Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development | Q34315320 | ||
| Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer | Q95383732 | ||
| Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database | Q34580491 | ||
| Expression profiling identifies microRNA signature in pancreatic cancer | Q34588109 | ||
| MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma | Q34604367 | ||
| A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile | Q34664680 | ||
| DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism | Q34773102 | ||
| MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3 | Q34989346 | ||
| The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival | Q35014682 | ||
| MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers | Q35113043 | ||
| Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study | Q35152701 | ||
| MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury. | Q35750622 | ||
| Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs | Q35982213 | ||
| MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer | Q36387904 | ||
| The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma | Q36685520 | ||
| Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer | Q36738876 | ||
| The Impact of Hemolysis on Cell-Free microRNA Biomarkers | Q36872732 | ||
| Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer | Q37605740 | ||
| The validity of circulating microRNAs in oncology: five years of challenges and contradictions. | Q38198366 | ||
| Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101 | Q38401277 | ||
| Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer | Q38851544 | ||
| Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
| miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin | Q39247434 | ||
| An allelic series of miR-17 ∼ 92-mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron | Q40883914 | ||
| Expression of microRNAs in patients with pancreatic cancer and its prognostic significance | Q43903534 | ||
| Contrasting liver function test patterns in obstructive jaundice due to biliary strictures [corrected] and stones | Q45206497 | ||
| Pancreatic Cancer | Q54135367 | ||
| Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study | Q54158534 | ||
| MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma | Q57247811 | ||
| Methods for measuring plasma hemoglobin in micromolar concentration compared | Q67737071 | ||
| Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer | Q83121081 | ||
| Pancreatic cancer | Q85895419 | ||
| MicroRNAs in cancer | Q86065522 | ||
| MicroRNA biomarkers in whole blood for detection of pancreatic cancer | Q87140824 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 775-781 | |
| P577 | publication date | 2018-04-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer | |
| P478 | volume | 267 |
| Q91932289 | miRFA: an automated pipeline for microRNA functional analysis with correlation support from TCGA and TCPA expression data in pancreatic cancer | cites work | P2860 |
Search more.